Trazodone for Sleep: Dosing, Effectiveness, and How It Compares to Zolpidem, Eszopiclone, and Melatonin

What Is Trazodone and Why Is It Used for Sleep?

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) approved by the FDA in 1981 for major depressive disorder. At the 150 to 600 mg doses used for depression, its sedating properties were noted immediately. Prescribers began using 25 to 100 mg doses specifically for insomnia, and today trazodone ranks among the three most prescribed sleep agents in outpatient practice in the United States, even though no sleep-specific FDA approval exists. A 2017 analysis in the Journal of Clinical Sleep Medicine found trazodone was the second most commonly prescribed medication for insomnia in a national ambulatory care database, trailing only zolpidem.

Its sedating effect at low doses comes primarily from histamine H1 receptor antagonism and alpha-1 adrenergic blockade, not from its serotonergic activity. Sleep-dose trazodone (50 mg) produces minimal serotonin transporter occupancy, which is why antidepressant effects do not occur at these doses. Patients do not need to have depression to use it. The pharmacology is closer to a sedating antihistamine than to an SSRI at these dose levels.

How Trazodone Works in the Brain at Sleep Doses

At 50 to 100 mg, trazodone's sedation arrives through two main receptor actions. First, it blocks H1 histamine receptors, the same pathway exploited by diphenhydramine (Benadryl). Second, it blocks alpha-1 adrenergic receptors, reducing the norepinephrine-driven arousal signal. These two mechanisms together produce sleep onset within 30 to 60 minutes for most patients.

Polysomnography data show that trazodone 50 mg increased slow-wave (deep) sleep time and reduced wake-after-sleep-onset (WASO) in a randomized crossover study of 15 healthy volunteers. This slow-wave sleep enhancement distinguishes trazodone from the Z-drugs (zolpidem, eszopiclone, zaleplon), which tend to suppress slow-wave sleep or leave it unchanged. For patients who feel unrefreshed despite adequate sleep duration, that distinction may matter clinically.

Trazodone does not bind GABA-A receptors, which is why it lacks the addiction potential, tolerance development, and withdrawal syndrome associated with benzodiazepines and Z-drugs.

Trazodone Dosing for Insomnia

The standard starting dose is 50 mg taken 30 minutes before bed. Clinicians may start at 25 mg in older adults or in patients sensitive to orthostatic hypotension. The dose can be increased to 75 to 100 mg if 50 mg produces insufficient sleep benefit after one to two weeks. Doses above 100 mg are rarely used for sleep alone because antidepressant side effects begin to emerge and next-day sedation becomes more likely.

The FDA label for trazodone hydrochloride (Desyrel) states the drug should be taken shortly after a meal or light snack to reduce dizziness and orthostatic hypotension. Taking it on an empty stomach increases peak plasma concentration and worsens side effects without improving sleep quality.

Dose adjustments in specific populations:

• Older adults (65+): Start at 25 mg. The half-life may extend to 12+ hours with hepatic aging, raising fall risk.
• Hepatic impairment: Reduce dose by 50% in moderate-to-severe liver disease.
• CYP3A4 inhibitors (ketoconazole, ritonavir): These can double trazodone plasma levels. Reduce dose accordingly.

Trazodone vs. Zolpidem (Ambien): A Direct Comparison

Zolpidem is a Schedule IV controlled substance that acts as a positive allosteric modulator at GABA-A receptors. The FDA approved zolpidem for short-term insomnia treatment, and its label specifically restricts use to the shortest duration consistent with treatment goals. Trazodone carries no such restriction.

A 2018 systematic review in Sleep Medicine Reviews compared trazodone and zolpidem across available randomized controlled trials and found comparable subjective sleep onset latency reduction, but trazodone produced less rebound insomnia on discontinuation. Zolpidem, by contrast, is associated with rebound insomnia, complex sleep behaviors (sleepwalking, sleep-driving), and a 2019 FDA black-box warning requiring prominent labeling of serious injury risk from these behaviors.

Zolpidem 10 mg has a half-life of approximately 2.5 hours in healthy adults, but active metabolites in women led the FDA in 2013 to halve the recommended dose for women to 5 mg. Trazodone's half-life of 5 to 9 hours is longer, but at 50 mg there is no sex-specific dosing difference recognized.

For patients who require sleep medication beyond four to six weeks, chronic insomnia guidelines from the American Academy of Sleep Medicine (AASM) recommend cognitive behavioral therapy for insomnia (CBT-I) as the first-line treatment and advise caution with extended Z-drug use. Trazodone's unscheduled status makes it a frequent choice when longer-duration pharmacotherapy is needed after CBT-I has been attempted or declined.

Trazodone vs. Eszopiclone (Lunesta)

Eszopiclone (Lunesta) is the only Z-drug FDA-approved without a duration restriction, a distinction that resulted from its longer key trial program. The SLEEP-1 trial demonstrated that eszopiclone 3 mg reduced subjective sleep onset latency and improved sleep maintenance over 6 months in patients with chronic primary insomnia. In SLEEP-1 (N=788), eszopiclone 3 mg reduced mean wake time after sleep onset by approximately 44 minutes vs. placebo over 6 months.

Eszopiclone is also Schedule IV. Its most commonly reported adverse effect is a metallic or bitter taste, occurring in roughly 34% of patients at 3 mg. Trazodone produces no taste disturbance. Eszopiclone can produce next-day psychomotor impairment; the FDA added a contraindication to driving the morning after taking the 3 mg dose.

Trazodone has not been studied in a trial of comparable size or duration to SLEEP-1 for the specific insomnia indication. That evidence gap is a real limitation. Clinicians who prefer trazodone for long-term use are relying on a combination of smaller trials, mechanistic reasoning, and its favorable non-controlled status, not on a matched evidence base.

Trazodone vs. Zaleplon (Sonata)

Zaleplon has the shortest half-life of the Z-drugs at approximately 1 hour. It is FDA-approved for sleep onset insomnia and can be taken in the middle of the night (provided at least 4 hours remain before waking). The ultra-short half-life minimizes next-day sedation but provides essentially no sleep maintenance benefit.

Trazodone, with its 5, 9-hour half-life, addresses both sleep onset and sleep maintenance. Patients with frequent awakenings after sleep onset are generally better served by trazodone than zaleplon. For patients whose only complaint is taking too long to fall asleep, zaleplon's single-purpose pharmacokinetics may be preferable.

Zaleplon 10 mg reduced subjective sleep onset latency by approximately 15 minutes vs. placebo in a pooled analysis of Phase III trials. A direct head-to-head trial of zaleplon vs. trazodone for insomnia has not been published.

Trazodone vs. Melatonin

Melatonin is an endogenous hormone produced by the pineal gland in response to darkness. Exogenous melatonin supplements (0.5 to 5 mg) advance circadian phase and reduce sleep onset latency by an average of 7 minutes in meta-analytic data. A 2013 Cochrane review (19 trials, N=1,683) found melatonin reduced sleep onset latency by a mean of 7.06 minutes (95% CI: 4.37, 9.75) vs. placebo and is most effective for circadian rhythm sleep disorders such as jet lag and delayed sleep phase.

The 7-minute mean reduction is modest. Melatonin is not effective for primary chronic insomnia in most patients. The American Academy of Sleep Medicine's 2017 clinical practice guideline explicitly states: "We suggest that clinicians not use melatonin as a treatment for sleep onset or sleep maintenance insomnia (vs. no treatment) in adults."

Trazodone, even without a dedicated Phase III insomnia trial, produces substantially larger reductions in sleep onset latency and wake-after-sleep-onset than melatonin in the available comparator data. For patients with true insomnia disorder (not jet lag or shift-work circadian misalignment), trazodone is the pharmacologically stronger choice.

Melatonin's advantages are real: it is over-the-counter, inexpensive, and carries no dependence risk. For mild sleep difficulty or travel-related sleep disruption, melatonin remains a reasonable first option before escalating to prescription therapy.

Side Effects and Safety of Trazodone at Sleep Doses

The most common adverse effects at 50 to 100 mg are:

• Daytime drowsiness or grogginess (reported in 10 to 20% of patients in available trials)
• Orthostatic hypotension and dizziness (particularly in the first week and on an empty stomach)
• Dry mouth
• Blurred vision

Rare but serious adverse effects include:

• Priapism: Prolonged, painful erection occurring in approximately 1 in 6,000 male patients. Any erection lasting more than 2 hours requires emergency evaluation. Trazodone should be used with extreme caution in men with sickle cell anemia or on phosphodiesterase-5 inhibitors.
• QTc prolongation: Trazodone prolongs the QT interval in a dose-dependent manner. The sleep dose range (25 to 100 mg) produces minimal QT prolongation in patients without underlying cardiac disease, but combination with other QT-prolonging agents (antipsychotics, certain antibiotics) requires ECG monitoring.
• Serotonin syndrome: Rare at sleep doses, but possible when combined with MAOIs, linezolid, methylene blue, or high-dose serotonergic antidepressants.

A 2020 pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS) found that trazodone's reporting odds ratio for falls in older adults was 2.1 (95% CI: 1.8, 2.5), underscoring the need for low starting doses in patients 65 and older.

Who Is a Good Candidate for Trazodone Sleep Therapy?

Trazodone fits well for patients who:

• Have chronic insomnia and have completed or declined CBT-I
• Need longer-duration pharmacotherapy without a controlled substance
• Have comorbid depression or anxiety where a low-dose sedating agent might address both symptoms
• Are currently taking a stimulating antidepressant (bupropion, fluoxetine) and need sleep augmentation
• Have a history of substance use disorder, making Schedule IV medications undesirable

Trazodone is a poor fit for patients who:

• Are male with a history of priapism or anatomical penile conditions
• Are on MAOIs or linezolid
• Have uncontrolled QT prolongation or are on multiple QT-prolonging drugs
• Are in the first trimester of pregnancy (teratogenicity data are limited)

The HealthRX clinical team uses the following triage framework when evaluating a new insomnia patient for pharmacotherapy after CBT-I referral:

Step 1. Confirm insomnia subtype: sleep onset only, sleep maintenance only, or mixed. Step 2. Screen for substance use history, cardiac QT status, sex (priapism risk), and concurrent serotonergic medications. Step 3. If sleep onset only and circadian misalignment suspected: trial melatonin 0.5 to 3 mg for 2 weeks. Step 4. If mixed insomnia, no controlled-substance contraindication, short-term use acceptable: consider zolpidem 5 mg (women) or 10 mg (men) for up to 4 weeks. Step 5. If longer-duration pharmacotherapy is needed, substance use history is present, or the patient declines controlled substances: start trazodone 50 mg at bedtime, titrate to 100 mg after 2 weeks if response is inadequate. Step 6. Re-evaluate at 4 weeks, 12 weeks, and every 6 months for continued indication.

What the AASM Guidelines Say About Trazodone

The AASM published clinical practice guidelines for chronic insomnia disorder in adults in 2017. The 2017 AASM guideline states: "We suggest that clinicians use trazodone (vs. no treatment) as a treatment for sleep onset insomnia and sleep maintenance insomnia in adults with chronic insomnia disorder." The recommendation carries a "weak" grade due to limited high-quality trial data, not due to evidence of harm.

The same guideline document provides a "strong" recommendation for CBT-I as the first-line treatment, with pharmacotherapy as an adjunct or alternative when CBT-I is not accessible or not effective. Access to CBT-I remains limited in the United States: a 2022 study estimated that fewer than 1% of adults with insomnia disorder receive CBT-I from a trained provider, largely due to shortage of trained therapists and inadequate insurance reimbursement. For the remaining 99%, pharmacotherapy is the practical reality.

Drug Interactions to Know Before Starting Trazodone

Trazodone is metabolized primarily by CYP3A4. Drugs that inhibit CYP3A4 raise trazodone plasma levels; inducers lower them.

CYP3A4 inhibitors (raise trazodone levels): Ketoconazole, itraconazole, ritonavir, clarithromycin, grapefruit juice in high amounts.

CYP3A4 inducers (lower trazodone levels): Rifampin, carbamazepine, phenytoin, St. John's Wort.

CNS depressants: Alcohol, benzodiazepines, opioids, and antihistamines add to trazodone's sedating effect. Combining trazodone 50 mg with alcohol 0.08 g/dL has been shown to produce additive psychomotor impairment.

Digoxin and phenytoin: Trazodone may increase plasma levels of both. Monitor levels if co-prescribed.

Monitoring and Discontinuing Trazodone

Unlike Z-drugs and benzodiazepines, trazodone does not produce physical dependence at hypnotic doses. No gradual taper is required when stopping 50 to 100 mg after short-term use. Patients who have used 100 mg nightly for several months may experience a brief return of insomnia symptoms (two to five nights) after stopping, but this is not a physiological withdrawal syndrome.

Clinicians should reassess at each follow-up whether continued pharmacotherapy is still needed. Insomnia often remits with treatment of the underlying comorbidity (depression, anxiety, pain, sleep apnea). Prescribing trazodone indefinitely without reassessment is not appropriate practice.

A 2019 review in Annals of Internal Medicine concluded that long-term use of any sedative-hypnotic, including trazodone, is associated with falls, cognitive impairment, and motor vehicle accidents in adults over 65, and recommended annual reassessment of sleep medication necessity in this population.

At the 12-month mark, patients using trazodone for sleep should be offered a trial discontinuation or a structured CBT-I course, regardless of age.